Page 172 - Read Online

Zhang et al. Hepatoma Res 2019;5:14 I http://dx.doi.org/10.20517/2394-5079.2018.117 Page 9 of 9

53. Fu Y, Xu X, Huang D, Cui D, Liu L, et al. Plasma heat shock protein 90alpha as a biomarker for the diagnosis of liver cancer: an
official, large-scale, and multicenter clinical trial. EBioMedicine 2017;24:56-63.
54. Shen Q, Fan J, Yang XR, Tan Y, Zhao W, et al. Serum DKK1 as a protein biomarker for the diagnosis of hepatocellular carcinoma: a
large-scale, multicentre study. Lancet Oncol 2012;13:817-26.
55. Abdel Wahab AHA, El-Halawany MS, Emam AA, Elfiky A, Abd Elmageed ZY. Identification of circulating protein biomarkers in
patients with hepatocellular carcinoma concomitantly infected with chronic hepatitis C virus. Biomarkers 2017;22:621-8.
56. Zhang S, Jiang K, Zhang Q, Guo K, Liu Y. Serum fucosylated paraoxonase 1 as a potential glycobiomarker for clinical diagnosis of
early hepatocellular carcinoma using ELISA Index. Glycoconj J 2015;32:119-25.
57. Zhang W, Chen J, Wu M, Zhang X, Zhang M, et al. PRMT5 restricts hepatitis B virus replication through epigenetic repression of
covalently closed circular DNA transcription and interference with pregenomic RNA encapsidation. Hepatology 2017;66:398-415.
58. Ganem D, Prince AM. Hepatitis B virus infection - natural history and clinical consequences. N Engl J Med 2004;351:351.
59. Cheng HY, Kang PJ, Chuang YH, Wang YH, Jan MC, et al. Circulating programmed death-1 as a marker for sustained high hepatitis
B viral load and risk of hepatocellular carcinoma. PLos One 2014;9:e95870.
60. Durantel D, Zoulim F. New antiviral targets for innovative treatment concepts for hepatitis B virus and hepatitis delta virus. J Hepatol
2016;64:S117-S131.
61. Zhang X, Zhang H, Ye L. Effects of hepatitis B virus X protein on the development of liver cancer. J Lab Clin Med 2006;147:58-66.
62. Zhang XD, Wang Y, Ye LH. Hepatitis B virus X protein accelerates the development of hepatoma. Cancer Biol Med 2014;11:182-90.
63. Gao Y, Feng J, Yang G, Zhang S, Liu Y, et al. Hepatitis B virus X protein-elevated MSL2 modulates hepatitis B virus covalently
closed circular DNA by inducing degradation of APOBEC3B to enhance hepatocarcinogenesis. Hepatology 2017;66:1413-29.
64. Zhang H, Wu LY, Zhang S, Qiu LY, Li N, et al. Anti-Hepatitis B virus X protein in sera is one of the markers of development of liver
cirrhosis and liver cancer mediated by HBV. J Biomed Biotechnol 2009;2009:289068.
65. Zhang S, Gao S, Zhao M, Liu Y, Bu Y, et al. Anti-HBV drugs suppress the growth of HBV-related hepatoma cells via down-regulation
of hepatitis B virus X protein. Cancer Lett 2017;392:94-104.
66. Xie QK, Zhao YJ, Pan T, Lyu N, Mu LW, et al. Programmed death ligand 1 as an indicator of pre-existing adaptive immune responses
in human hepatocellular carcinoma. Oncoimmunology 2016;5:e1181252.
67. Sun J, Jiang W, Tian D, Guo Q, Shen Z. Icotinib inhibits the proliferation of hepatocellular carcinoma cells in vitro and in vivo
dependently on EGFR activation and PDL1 expression. Onco Targets Ther 2018;11:8227-37.
68. Mocan T, Sparchez Z, Craciun R, Bora CN, Leucuta DC. Programmed cell death protein-1 (PD-1)/programmed death-ligand-1 (PD-
L1) axis in hepatocellular carcinoma: prognostic and therapeutic perspectives. Clin Transl Oncol 2018. [DOI: 10.1007/s12094-018-
1975-4]
69. El-Khoueiry AB, Sangro B, Yau T, Crocenzi TS, Kudo M, et al. Nivolumab in patients with advanced hepatocellular carcinoma
(CheckMate 040): an open-label, non-comparative, phase 1/2 dose escalation and expansion trial. Lancet 2017;389:2492-502.
70. Raoul JL, Kudo M, Finn RS, Edeline J, Reig M, et al. Systemic therapy for intermediate and advanced hepatocellular carcinoma:
sorafenib and beyond. Cancer Treat Rev 2018;68:16-24.
71. Best J, Schotten C, Lohmann G, Gerken G, Dechene A. Tivantinib for the treatment of hepatocellular carcinoma. Expert Opin
Pharmacother 2017;18:727-33.
72. Ikeda K, Kudo M, Kawazoe S, Osaki Y, Ikeda M, et al. Phase 2 study of lenvatinib in patients with advanced hepatocellular carcinoma.
Journal of Gastroenterology 2017;52:512-9.
73. Bruix J, Qin S, Merle P, Granito A, Huang YH, et al. Regorafenib for patients with hepatocellular carcinoma who progressed on
sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet 2017;389:56-66.
74. Finn RS, Merle P, Granito A, Huang YH, Bodoky G, et al. Outcomes of sequential treatment with sorafenib followed by regorafenib
for HCC: Additional analyses from the phase III RESORCE trial. J Hepatol 2018;69:353-8.
75. Abou-Alfa GK, Meyer T, Cheng AL, El-Khoueiry A, Rimassa L, et al. Cabozantinib (C) versus placebo (P) in patients (pts) with
advanced hepatocellular carcinoma (HCC) who have received prior sorafenib: Results from the randomized phase 3 CELESTIAL trial.
J Clin Oncol 2018;36.
76. Khoja L, Butler MO, Kang SP, Ebbinghaus S, Joshua AM. Pembrolizumab. J Immunother Cancer 2015;3:36.
77. Zhu AX, Ryoo BY, Yen CJ, Kudo M, Poon RTP, et al. Ramucirumab (RAM) as second-line treatment in patients (pts) with advanced
hepatocellular carcinoma (HCC): Analysis of patients with elevated alpha-fetoprotein (AFP) from the randomized phase III REACH
study. J Clin Oncol 2015;33.
78. Yakes FM, Chen J, Tan J, Yamaguchi K, Shi Y, et al. Cabozantinib (XL184), a novel MET and VEGFR2 inhibitor, simultaneously
suppresses metastasis, angiogenesis, and tumor growth. Mol Cancer Ther 2011;10:2298-308.
79. Zhu AX, Park JO, Ryoo BY, Yen CJ, Poon R, et al. Ramucirumab versus placebo as second-line treatment in patients with advanced
hepatocellular carcinoma following first-line therapy with sorafenib (REACH): a randomised, double-blind, multicentre, phase 3 trial.
Lancet Oncol 2015;16:859-70.
80. Kudo M, Ueshima K. Positioning of a molecular-targeted agent, sorafenib, in the treatment algorithm for hepatocellular carcinoma and
implication of many complete remission cases in Japan. Oncology 2010;78 Suppl 1:154-66.
81. Lu L, Lu M, Pei Y, Chen J, Qin L, Zhu W, Jia H. Down-regulation of SDF1-α expression in tumor microenvironment is associated
with aspirin-mediated suppression of the pro-metastasis effect of sorafenib in hepatocellular carcinoma. Acta Biochim Biophys Sin
2015;47:988-96.